G
Gerald Y. Minuk
Researcher at University of Manitoba
Publications - 238
Citations - 6490
Gerald Y. Minuk is an academic researcher from University of Manitoba. The author has contributed to research in topics: Liver disease & Hepatitis. The author has an hindex of 40, co-authored 232 publications receiving 6116 citations. Previous affiliations of Gerald Y. Minuk include Icahn School of Medicine at Mount Sinai & University of Calgary.
Papers
More filters
Journal ArticleDOI
The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
E. Jenny Heathcote,K Cauch-Dudek,Valery Walker,Robert J Bailey,Laurence M. Blendis,Cameron N. Ghent,Pina Michieletti,Gerald Y. Minuk,S. Chris Pappas,Linda J. Scully,Urs P. Steinbrecher,Lloyd R. Sutherland,C. Noel Williams,Helga Witt-Sullivan,Lawrence Worobetz,Ruth Milner,Ian R. Wanless +16 more
TL;DR: Although treatment was not associated with any improvement in symptoms, ursodeoxycholic acid therapy caused the bilirubin to fall significantly within the first 3 mo of therapy (p<0.001), which led to an improvement in serum markers of cholestasis.
Journal ArticleDOI
Fatty infiltration of liver in hyperlipidemic patients.
TL;DR: It is indicated that ultrasonographic evidence of fatty infiltration of the liver is evident in approximately 50% of patients with hyperlipidemia, and diabetes was the only risk factor other than hypertriglyceridemia that was significantly associated with fatty infiltration.
Journal ArticleDOI
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Henry Lik-Yuen Chan,E. Jenny Heathcote,Patrick Marcellin,Ching-Lung Lai,Mong Cho,Young Myung Moon,You-Chen Chao,Robert P. Myers,Gerald Y. Minuk,Lennox J. Jeffers,William Sievert,Natalie Bzowej,George Harb,Ralf Kaiser,Xin-Jian Qiao,Nathaniel A. Brown +15 more
TL;DR: Telbivudine demonstrated greater and more consistent HBV DNA suppression than adefovir after 24 weeks of treatment, and was not of sufficient size or duration to compare clinical outcomes and long-term efficacy.
Journal ArticleDOI
A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
Jenny Heathcote,John G. McHutchison,Samuel Lee,Myron J. Tong,Kent G. Benner,Gerald Y. Minuk,Teresa L. Wright,John Fikes,Brian D. Livingston,Alex Sette,Robert Chestnut +10 more
TL;DR: Administration of the single‐epitope vaccine, CY‐1899, initiated CTL activity, but of a magnitude lower than that observed during spontaneous HBV clearance, and this low‐level C TL activity was not associated with viral clearance.
Journal ArticleDOI
Shear stress-induced nitric oxide release triggers the liver regeneration cascade.
TL;DR: Support is provided for the hypothesis that a hemodynamic change results in increased shear stress in the liver causing generation of NO, which then triggers the liver regeneration cascade.